Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Public ClinicalTrials.gov record NCT06449209. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.
Study identification
- NCT ID
- NCT06449209
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 110 participants
Conditions and interventions
Interventions
- BNT327 Dose Level 1 (DL1) Drug
- BNT327 Dose Level 2 (DL2) Drug
- Etoposide Drug
- Carboplatin Drug
- Paclitaxel Drug
- Topotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2024 (Actual)
- Primary completion
- Jun 2027 (Estimated)
- Completion
- Feb 2028 (Estimated)
- Last update posted
- Sep 14, 2026
2024 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology, LLC | Anchorage | Alaska | 99508 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| Clermont Oncology Center | Clermont | Florida | 34711 | — |
| Hematology Oncology Associates of Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Tallahassee Memorial Physician Partners - Cancer & Hematology Specialists | Tallahassee | Florida | 32308 | — |
| Carle Foundation Hospital d/b/a Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Fort Wayne Medical Oncology and Hematology, Inc | Fort Wayne | Indiana | 46804 | — |
| University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center) | Lexington | Kentucky | 40536 | — |
| Allina Health | Minneapolis | Minnesota | 55407 | — |
| SSM Health Cancer Care - St. Clare | Fenton | Missouri | 63026 | — |
| Nebraska Hematology-Oncology (NHO) - Lincoln | Lincoln | Nebraska | 68506 | — |
| Clinical Research Alliance Inc | Westbury | New York | 11590 | — |
| Haywood Infusion Center | Clyde | North Carolina | 28721-8046 | — |
| FirstHealth Outpatient Cancer Center | Pinehurst | North Carolina | 28374 | — |
| The Christ Hospital Cancer Center | Cincinnati | Ohio | 45219 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Millenium Research & Clinical Development | Houston | Texas | 77090 | — |
| SSM Health Cancer Care | Madison | Wisconsin | 53715 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06449209, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06449209 live on ClinicalTrials.gov.